The iHuPBMC-NK platform from InnoModels Biotechnology is an innovative technology that is leading the way in biomedical research, providing exceptional tools and resources to support researchers in the fields of immunotherapy, cancer research, infectious diseases, and more. The core of the platform lies in its ability to efficiently produce natural killer cells (NK cells) and its customized services for researchers.
First, the iHuPBMC-NK platform utilizes advanced cell culture and expansion technologies to efficiently obtain highly active and functionally intact NK cells from human peripheral blood mononuclear cells (PBMCs). This efficient production method allows researchers to obtain NK cells on a large scale, providing a sufficient source of cells for their research endeavors. At the same time, it also enables researchers to study the biological properties and functions of NK cells in greater depth, providing strong support for the development of immunotherapy, cancer research and other fields.
Secondly, the iHuPBMC-NK platform has a wide range of applications. NK cells are an important part of the immune system, and they play a key role in defending against pathogens and monitoring tumor cells. Therefore, the platform's products have a wide range of applications in several research fields, including immunotherapy, cancer research, and infectious diseases. Researchers can utilize these NK cells for in vitro experiments, drug screening, disease modeling studies, etc., so as to gain a deeper understanding of the pathogenesis of these diseases and find new treatments.

In addition, the iHuPBMC-NK platform offers customized services, providing different types and quantities of NK cells according to the specific needs of research projects. This personalized service approach allows researchers to flexibly choose the type and number of NK cells they need according to their research needs, thus better meeting their research demands.
It is worth mentioning that the iHuPBMC-NK platform also focuses on simulating clinical situations and using human NK cells during the production of NK cells to ensure that the experimental results truly reflect the drug response. In addition, the platform also focuses on the composition of NK cells, with more than 70% of the total NK cells being CD16+ cells. This composition ensures that the platform is able to accurately present the immune response, laying a solid foundation for reliable assessment. At the same time, the platform also successfully addresses the challenges posed by NK cell depletion, enabling researchers to more accurately assess antibody-dependent cell-mediated cytotoxicity (ADCC), NK-related immune checkpoints (e.g., NKG2A), and cytokine effects (e.g., hIL15).
In summary, the iHuPBMC-NK platform of InnoModels Biotechnology has become an innovative force in the field of biomedical research with its ability to produce NK cells efficiently, its wide range of application areas, and its customized services. Its emergence has provided researchers with abundant research resources and tools, and has pushed forward advances in immunotherapy, cancer research, infectious diseases and other fields, making significant contributions to human health. With the continuous progress of science and technology and in-depth research, it is believed that the iHuPBMC-NK platform will play a greater role in the future and bring more surprises and breakthroughs to the development of biomedical research field.